Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan R Martinez

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Novartis Foundation Symposium|November 12, 2003
(Pro)insulin-specific regulatory T cellsLeonard C Harrison, Natasha R Solly, Nathan R Martinez
The Journal of Clinical Investigation|January 24, 2002
Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunityArno Hänninen, Nathan R Martinez, Gayle M Davey, et al.
The Journal of Clinical Investigation|May 3, 2003
Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptideNathan R Martinez, Petra Augstein, Antonis K Moustakas, et al.
Plos One|November 5, 2014
High efficiency ex vivo cloning of antigen-specific human effector T cellsMichelle A Neller, Michael H-L Lai, Catherine M Lanagan, et al.
Melanoma Research|September 22, 2007
Dendritic cell immunotherapy for stage IV melanomaMichael G E O'Rourke, Maree K Johnson, Catherine M Lanagan, et al.
Immunology and Cell Biology|May 10, 2006
Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanomaJulia A Marshall, Trevor H Forster, David M Purdie, et al.
Nature Nanotechnology|January 21, 2026
Engineered mucus-tethering bispecific nanobodies enhance mucosal immunity against respiratory pathogensLiming Zhao, Kyle L O'Donnell, Megha Dubey, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Novartis Foundation Symposium|November 12, 2003
(Pro)insulin-specific regulatory T cellsLeonard C Harrison, Natasha R Solly, Nathan R Martinez
The Journal of Clinical Investigation|January 24, 2002
Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunityArno Hänninen, Nathan R Martinez, Gayle M Davey, et al.
The Journal of Clinical Investigation|May 3, 2003
Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptideNathan R Martinez, Petra Augstein, Antonis K Moustakas, et al.
Plos One|November 5, 2014
High efficiency ex vivo cloning of antigen-specific human effector T cellsMichelle A Neller, Michael H-L Lai, Catherine M Lanagan, et al.
Melanoma Research|September 22, 2007
Dendritic cell immunotherapy for stage IV melanomaMichael G E O'Rourke, Maree K Johnson, Catherine M Lanagan, et al.
Immunology and Cell Biology|May 10, 2006
Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanomaJulia A Marshall, Trevor H Forster, David M Purdie, et al.
Nature Nanotechnology|January 21, 2026
Engineered mucus-tethering bispecific nanobodies enhance mucosal immunity against respiratory pathogensLiming Zhao, Kyle L O'Donnell, Megha Dubey, et al.
Pageof 1